Every round on record, with the sources behind each and the investors on them.
Yicura BioMed develops innovative DNA medicines and antibody immunotherapies for treating cancers, inflammatory, and infectious diseases.
yicura.hkHong KongBiotechFounded 2015
4 sources · checked 2 times, last 6h ago
Developing: it holds up against its sources so far, and firms up as more reporting lands.
Sources agree; the amount and participating investors were not disclosed. AEF Greater Bay Area Fund is identified only as the lead of the earlier Series A.
| Round | Amount | Announced | Lead | Buzz |
|---|---|---|---|---|
| Series B | n/a | 2026-11-12 | Gobi Partners | 4 outlets. #50 in Trending |
4 sources · checked 2 times, last 6h ago [ DEVELOPING ] Developing: it holds up against its sources so far, and firms up as more reporting lands. read against 4 sources
Sources agree; the amount and participating investors were not disclosed. AEF Greater Bay Area Fund is identified only as the lead of the earlier Series A. | ||||
Yicura BioMed develops innovative DNA medicines and antibody immunotherapies for cancers, inflammatory diseases, and infectious diseases.
Yicura is pursuing a potential functional HIV cure with ICVAX while developing an anti-Δ42PD1 antibody platform for cancers and other serious unmet medical needs. Its latest Series B first closing, led by Gobi Partners, is intended to move ICVAX toward Phase II and accelerate the cancer vaccine and antibody pipeline, although the amount and full-round target were not disclosed.
Checked against 10 sources today
Also named as backers in company research: Gobi Partners GBA, AEF Greater Bay Area Fund
| EARLIER ROUNDS FROM COMPANY RESEARCH · DEVELOPING | ||||
| Series A | US$12 million | undated | AEF Greater Bay Area Fund managed by Gobi Partners GBA | |